Fig. 5
From: Identification of the S100 fused-type protein hornerin as a regulator of tumor vascularity
Dynamic contrast-enhanced magnetic resonance imaging reveals decreased vascularity and perfusion in Hrnr siRNA-treated mice compared to control mice. a Representative axial time course images of gadolinium-DTPA (Gd-DTPA) uptake taken pre-siRNA treatment (top row) and 6 days post-treatment (bottom row). The kidney (“K”) is labeled for reference. Scr siRNA and Hrnr siRNA tumors demarcated by a white dashed line. b The concentration of Gd-DTPA (mM) in the tumors was plotted over time. N = 7 tumors/treatment group. Injection of Gd-DTPA is signified by arrowhead. c K trans was calculated for both pre-treatment and post-treatment tumors. N = 7 tumors/treatment group. Scale bar = 2 mm. Graphs represent mean ± SEM. *P < 0.05 by unpaired two-tailed t-test
